Genmab — April 2016
-
Når man eksempelvis kigger på Celgenes PDE4 inhibitor Apremilast, som de lancerede i Q4 2014, så sælger den ganske imponerende efterhånden. Små 200 millioner dollar her i Q1 2016, så markedet for orale psoriasis midler er der i hvert brug for. Ser stadig gode muligheder for, at man med en RORgt inhibitor kan opnå bedre effekt end eks. en PDE4 inhibitor, så Vitae skal bare tage sig sammen
-
Synes stadig det er forkasteligt at CEO plus en anden ledende medarbejde kunne sælge aktier den 30/12, når de helt sikkert viste at man ikke indrullede alle patienter. Så fik de lige solgt til kurs 18 og kort tid efter kunne vi andre sælge til kurs 4
!! Not nice - not nice at all
-
Vedr. rekruttering til Castor og Pollux sagde Jan på CC efter Q4, 2014 sådan: Thanks, Michael for the questions. Let me start with question two actually, the trial, the Phase 3 trial with Revlimid-Idelalisib [ph]or without daratumumab is recruiting very, very rapidly and much ahead of schedule and hopefully we can give you soon recruitment updates on that study. And thus far the recruitment has exceeded all of Janssen’s expectations by a lot, I can tell you. Also the Velcade-dex-dara combination
-
-
wauw - check lige IMGN her i åbningen!
-
og store prygl til GILD som forventet
-
ImmunoGen Reports Wider Q3 Loss Vs. Street, Misses on Revenue; Lowers FY16 Revenue Outlook Below Forecasts<IMGN.OQ> - MT Newswires
29-Apr-2016 13:15:18
07:09 AM EDT, 04/29/2016 (MT Newswires) -- ImmunoGen (IMGN) reported Friday that
for Q3 ended March 31, its loss was wider than expected, and revenue fell short
of analysts' estimates; it also lowered its revenue guidance for fiscal 2016
below Street forecasts.The clinical-stage biotechnology company posted Q3 net loss of $31.9 million, or
$0 -
det kan vist ikke betale sig at skuffe forventninger i det her marked....
-
IMGN justerede guidance - 2016 guidance for its net loss is now expected to be between $135 million and $140 million, versus previous estimate of $120 million and $125 million
-
så ikke noget med klinikken
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind